unbelievable value at this level, page-12

Although we have a bucket load of shares, the market cap is only $85 million. If the drug is promising or if there is some news such as commencement of phase 2b trials or orphan drug status the SP will at least double. The only risk is of failure of CVAC. But this risk will not eventuate until the phase 2b trials are well underway/complete. Meanwhile the SP will surely creep up. This is a no-brainer. The number of shares is irrelevant. The value of PRR if CVAC is successful will be in billions. Meanwhile the SP will keep rising in anticipation of success/ making millions.